Acute NADPH oxidase activation potentiates cerebrovascular permeability response to bradykinin in ischemia–reperfusion  by Woodfin, Abigail et al.
Free Radical Biology & Medicine 50 (2011) 518–524
Contents lists available at ScienceDirect
Free Radical Biology & Medicine
j ourna l homepage: www.e lsev ie r.com/ locate / f reeradb iomedOriginal Contribution
Acute NADPH oxidase activation potentiates cerebrovascular permeability response
to bradykinin in ischemia–reperfusion
Abigail Woodﬁn 1, De-En Hu 2, Mosharraf Sarker 3, Tsuyoshi Kurokawa 4, Paul Fraser ⁎
BHF Centre of Research Excellence, Cardiovascular Division, King's College London, London SE1 9NH, UK⁎ Corresponding author. Fax: +44 20 7848.
E-mail address: paul.fraser@kcl.ac.uk (P. Fraser).
1 Present address: Centre for Microvascular Research,
Medicine and Dentistry, London EC1M 6BQ, UK.
2 Present address: Department of Biochemistry, Unive
CB2 1QW, UK.
3 Present address: School of Science & Technol
Middlesbrough TS1 3BA, UK.
4 Present address: Department of Surgery, Aichi Medi
480-1195, Japan.
0891-5849 © 2010 Elsevier Inc.
doi:10.1016/j.freeradbiomed.2010.12.010
Open access under CC BY-NCa b s t r a c ta r t i c l e i n f oArticle history:
Received 9 August 2010
Revised 12 November 2010
Accepted 8 December 2010
Available online 16 December 2010
Keywords:
Blood–brain barrier
Interleukin-1β
Bradykinin
NADPH oxidase
Free radicalsFree radical generation is a key event in cerebral reperfusion injury. Bradykinin (Bk) and interleukin-1β (IL-
1β) have both been implicated in edema formation after stroke, although acute Bk application itself results in
only a modest permeability increase. We have investigated the molecular mechanism by assessing the
permeability of single pial venules in a stroke model. Increased permeability on reperfusion was dependent
on the duration of ischemia and was prevented by applying the B2 receptor antagonist HOE 140.
Postreperfusion permeability increases were mimicked by applying Bk (5 μM) for 10 min and blocked by
coapplying the IL-1 receptor antagonist with Bk. Furthermore, 10 min pretreatment with IL-1β resulted in a 3
orders of magnitude leftward shift of the acutely applied Bk concentration–response curve. The left shift was
abolished by scavenging free radicals with superoxide dismutase and catalase. Apocynin coapplied with IL-1β
completely blocked the potentiation, implying that NADPH oxidase assembly is the immediate target of IL-1β.
In conclusion, this is ﬁrst demonstration that bradykinin, released during cerebral ischemia, leads to IL-1β
release, which in turn activates NADPH oxidase leading to blood–brain barrier breakdown.Barts and The London School of
rsity of Cambridge, Cambridge
ogy, University of Teesside,
cal University, Nagakute, Aichi
-ND license.© 2010 Elsevier Inc. Open access under CC BY-NC-ND license.The processes underlying the life-threatening edema following
disruption of the blood–brain barrier after stroke and trauma are still
obscure. Interleukin-1β (IL-1β), which can be released rapidly after a
noxious stimulus to a number of cells, is one of the proinﬂammatory
cytokines that play a role in cerebral ischemia [1] and has been
implicated in subsequent destruction of brain cells [2]. These
responses mainly involve gene transcription and new protein
synthesis and are therefore relatively slow in onset, but are triggered
by rapid signaling from the receptor to the nucleus. The kinase
signaling cascades are still only partially characterized, but are
increasingly recognized as involving the controlled generation of
reactive oxygen species (ROS) acting as signaling intermediates, in
contrast to their traditional cytotoxic role [3–6]. There is accumulating
evidence that reperfusion after ischemia results in a surge of free
radical generation [7] that sets in train a sequence of events that lead
to highly destructive cerebral edema [8].
Inﬂammatory mediators, such as bradykinin, histamine, angioten-
sin II, and substance P, act via endothelial G-protein-coupled receptors(GPCR) and have been characterized in terms of rapid signaling
responses, including elevated Ca2+ or cGMP; secretion of vasoactive
mediators such as NO, PGI2, and EDHFwithin seconds orminutes; and
transient increased microvascular permeability. It is clear, however,
that at least some GPCR agonists (e.g., AT II and thrombin) can in
addition cause longer term changes in endothelial cell phenotype and
can stimulate the generation of reactive oxygen species [9–11].
Bradykinin, in particular, is one substance that has been implicated in
the development of the damage that follows cerebral ischemia [12],
including cerebral edema, but as acute bradykinin administration
results in only a small permeability change in the cerebral endothe-
lium [13], the mechanisms underlying subsequent longer term
damage remain to be elucidated.
Little is known about the potential interactions between the IL-1β
and the GPCR signaling pathways in the vasculature. This study
provides evidence for bradykinin (Bk) and IL-1β being released after
ischemia–reperfusion injury into the rat cerebral microcirculation to
activate independent signaling pathways that interact, resulting in
enhanced cerebrovascular permeability. This study, to our knowledge,
documents the ﬁrst report of novel interactions between these
inﬂammatory mediators to potentiate free radical generation.
Methods
Animals and experiments on single cerebral microvessels
Themethods used in this study, and its theoretical basis, have been
described previously [14]. Experiments were performed on Wistar
519A. Woodﬁn et al. / Free Radical Biology & Medicine 50 (2011) 518–524rats (age 20–30 days, of either sex) within guidelines directed by
the UK Home Ofﬁce Animals (Scientiﬁc Procedures) Act, 1986,
and local ethics committee guidelines, which conform with the
Guide for the Care and Use of Laboratory Animals published by the U.S.
National Institutes of Health (NIH Publication No. 85-23, revised
1996). Animals were anesthetized by an intraperitoneal injection of
60 mg kg−1 bodywt sodium pentobarbital diluted in water (25%w/v)
andmaintained by supplementary injection of 10% of the original dose
when necessary. At the end of the experiment the animals were killed
by administration of an overdose of the anesthetic.
Single-vessel experiments
The pial microcirculation of the surface of the brain was viewed
through a Zeiss ACM ﬂuorescence microscope under 525 to 535 nm
illumination, and sulforhodamine B (580 Da) was given via a bolus
injection into the carotid artery. The ﬂuorescent signal was analyzed
using a video-densitometer. Permeabilitywasmeasured in a single pial
venular capillary (diameter between 8 and 28 μm) from the rate of loss
of dye trapped by a glass-occluding probe [14]. Transient ischemiawas
induced by the injection of degradable starch microspheres [15].
Analysis of bradykinin in brain superfusate
Samples were collected from a specially made cup, which was
sealed to the skull after the dura and arachnoid were removed. The
cup volume was about 100 μl, and 50-μl aliquots of artiﬁcial
cerebrospinal ﬂuid, containing captopril (1 μM) and phosphoramidon
(200 μM) to block kinin-destroying enzymes (without which there
was too little Bk to measure), were removed and replenished at 5-min
intervals before and after administration of the starch microspheres
for a total of 70 min in all cases. Possible contamination by plasmawasFig. 1. The role of bradykinin in cerebrovascular permeability after cerebral ischemia. (A) Th
ischemia. Including SOD and catalase in the superfusate reduced this permeability incre
(regression coefﬁcients are all signiﬁcantly different from each other at pb0.001, analysis of
vessel followed before and after ischemia–reperfusion showing that HOE 140 application re
before ischemia. (C) Summary of HOE 140 post-ischemia–reperfusion permeability reduc
application is shown from eight venules from eight animals (pb0.005, paired t test). (D) Im
from the beginning of ischemia increased signiﬁcantly with the duration of ischemia (pb0.monitored from a prior intravenous injection of rhodamine–albumin
and examination of aliquots of sample ﬂuid in a microﬂuorimeter.
Samples that gave a reading higher than background were discarded.
The ﬂuid samples were stored at −20 °C until analyzed. Kinins were
extracted by using Sep-Pak Vac C18 cartridges and bradykinin-like
immunoreactivity was measured [16]. The radioimmunoassay range
was from 8 to 4000 fmol per tube. The Bk antibody shows N80% cross-
reactivity with kallidin and about 80% with Ile-Ser-Bk, which is one of
the kinins found in rat brain [17], but none with des(Arg9)-Bk.
Measurement of ROS generation in brain tissue
Wistar rats of weight between 200 and 250 g were killed by
exposure to CO2 and the brains were removed. The cerebellum was
discarded and the cerebral hemispheres were cut into pieces of
approximately 0.2 g and placed in thewells of a 96-well plate in 200 μl
balanced salt solution. Some tissues were pretreatedwith 30 pM IL-1β
in balanced salt solution (BSS; NaCl 192.5 mM, KCl 5 mM, MgCl2
1 mM, Hepes 10 mM, glucose 10 mM, CaCl2 1 mM, and 1% BSA) for
10 min. The BSS was removed and replaced with 50 μl Amplex red
(100 μM and 0.2 U/ml horseradish peroxidase) solution [18]. The
agonist was added to the wells and the ﬂuorescence measured at
15 min in a plate reader (Titertek Fluoroskan II) with 544 nm
excitation and 590 nm emission wavelengths. Each piece of tissue
was weighed and the readings were normalized to the weight.
All chemicals were purchased from Sigma, apart from the Amplex
red, which was purchased from Molecular Probes.
Statistics
Unless otherwise stated, the results are expressed as the mean±
standard error of the mean. Sigmoidal concentration–response curvese permeability of pial venules increased following reperfusion after a deﬁned period of
ase, whereas the bradykinin B2 antagonist HOE 140 resulted in a greater reduction
covariance; one vessel from one animal for each data point). (B) Permeability of a single
versibly reduces the permeability increase. The open symbol indicates the permeability
tion similar to (B); in which the permeability immediately before and after HOE 140
munoreactive bradykinin increase in ﬂuid collected from the brain surface over 70 min
05, each point from a single animal).
Fig. 2. Role of IL-β in permeability response to bradykinin. (A) High concentration of Bk
(5 μM) applied for 10 min resulted in raised permeability that did not reverse after its
removal, but remained raised. Permeability increased, without further Bk addition,
30 min after its ﬁrst application. IL-1ra (5 nM, open symbols) coapplied with Bk
resulted in a similar permeability increase and similar sustained increase, but then fell.
The differences beyond the 35-min point were signiﬁcantly different (pb0.001, t test; 4
vessels from 4 animals in each group). (B) Permeability response to a brief low-
concentration Bk application (50 nM) that was just detectible was much enhanced after
10 min IL-1β (30 pM) application (4 vessels from 4 animals). This potentiated response
to Bk was stable for 30 min after IL-1β was applied and thereafter increased further.
Cycloheximide (CHX; 100 μM; 5 vessels from 5 animals) treatment did not affect the
initial IL-1β potentiation of the response to Bk, but did block the subsequent increase.
All the Bk and BK+CHX responses after 20 min were signiﬁcantly greater than the
controls (pb0.05, paired t test), and those at 50 and 90 min were signiﬁcantly different
(pb0.001). (C) Concentration–response curves for bradykinin before and after
treatment with IL-1β. The log EC50 was signiﬁcantly left-shifted (pb0.05, F=11.38 at
1,7 df; data from 10 to 12 vessels from 12 animals).
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Software, San Diego, CA, USA).
Results
Microsphere-induced ischemia
Starch microspheres were infused into the internal carotid artery
and the permeability of a selected venular capillary, measured before
the infusion, was measured again as soon as ﬂow recommenced.
The blockage lasted from 5 to 60 min and the permeability increased
with the duration of the ischemia at the rate of 24.0±1.9×
10−6 cm s−1 h−1 (Fig. 1A). This rate of increase was much reduced
(11.9±0.6×10−6 cm s−1 h−1) when a free radical scavenging
mixture of superoxide dismutase and catalase (100 U ml−1 each)
was included in the superfusing solution during the blockage and
reduced much more (to 4.0±1.0×10−6 cm s−1 h−1) with the
bradykinin B2 receptor antagonist HOE 140 (1 μM). HOE 140
application during the reperfusion phase reversibly reduced the
increased permeability (Figs. 1B and C) after ischemia–reperfusion:
the mean permeability of 10.8±2.4×10−6 cm s−1 being reduced to
2.7±0.43×10−6 cm s−1. This evidence for bradykinin being contin-
uously generated after ischemia–reperfusion was conﬁrmed by
collecting ﬂuid from a cup placed over the cranial window: the total
immunoreactive bradykinin formed in the 70 min after ischemia was
also proportional to the duration of the ischemia (Fig. 1D).
We have previously shown that the response to acutely applied
bradykinin is stable in this preparation for up to 2 h for concentrations
up to 50 μM [13], and the foregoing data illustrate that bradykinin is
responsible for a considerable proportion of the raised permeability
during reperfusion, which is much greater than the maximum
response to acutely applied bradykinin [13].
Bradykinin-dependent permeability change
The idea that bradykinin plays a key role in the initial disruption of
the blood–brain barrier after ischemia–reperfusion was examined by
applying it at a high concentration (5 μM) for 10 min. The perme-
ability response was similar in magnitude to an acute application [13],
but did not reverse when the bradykinin was removed; permeability
remained raised, with a further increase that commenced 30 min after
the bradykinin application (Fig. 2A). This pattern was altered when
interleukin-1 receptor antagonist (IL-1ra) was coapplied with
bradykinin, and permeability returned to close to its initial value
10 min after the bradykinin+IL-1ra mixture was removed, which
indicates that bradykinin may be a factor in the rapid release of IL-1β.
The possible role of IL-1β in potentiating the permeability
response to Bk was further explored by applying it (30 pM) to the
brain surface for 10 min and testing the response to acute application
of a low Bk concentration (50 nM) that gave a just discernible stable
response (see Fig. 1 in Ref. [13]). Fig. 2B shows that IL-1β application
itself resulted in a small permeability increase, but after its removal
the response to bradykinin was potentiated. There are apparently two
phases in this response: an initial stable increase that lasts until
30 min after the start of IL-1β application and a second phase that
increases steadily to reach 4.0±0.6×10−6 cm s−1 at 90 min. The
likelihood that this secondary increase was due to the formation of
new protein was conﬁrmed by repeating the experiment in the
presence of cycloheximide (100 μM), when the permeability response
to acutely applied bradykinin (50 nM) remained stable at 1.1±
0.05×10−6 cm s−1 for 90 min (Fig. 2B). All subsequent experiments
on single microvessels described below were carried out in the
presence of cycloheximide (100 μM) to enable concentration–
response curves to be generated without the time-dependent
changes. In these experiments that effect of 10 min treatment with
IL-1β shifted the bradykinin permeability concentration–responsecurve to the left by about 3 orders of magnitude (log EC50 from
−6.7±0.28 before IL-1β to −9.7±0.25 after; Fig. 2C), without
affecting the maximal permeability response.
Signaling pathways
We have previously shown that the permeability response to
acute Bk application depends on the formation of ROS, as it was
inhibited by a combination of superoxide dismutase (SOD) and
catalase (100 U ml−1 each) [13] and furthermore was independent of
521A. Woodﬁn et al. / Free Radical Biology & Medicine 50 (2011) 518–524nitric oxide formation and soluble guanylyl cyclase (sGC) activation
[19]. In these experiments SOD and catalase also reduced the response
after treatment with IL-1β (Fig. 3A). The possibility that IL-1β
treatment activated the nitric oxide–sGC pathway was examined by
inhibiting endothelial NO synthase with L-N(G)-Nitroarginine methyl
ester (L-NAME), but this did not alter the potentiated permeability
response, nor did the sGC inhibitor 1 H-[1,2,4]-oxadiazolo-[4,3]-
quinoxalin-1-one (ODQ) alter the post-potentiated response to Bk
(Fig. 3B). It is therefore not surprising that the response to histamine,
which uses this NO-dependent pathway [20], was not affected by IL-
1β treatment (Fig. 3B). Fig. 3C shows that the acute response to a high
concentration of Bk (5 μM) was not affected by the protein kinase C
(PKC) antagonist calphostin C, and the possibility that IL-1β treatment
resulted in activation of such a PKC-dependent pathway was
examined by coapplying calphostin C with IL-1β. The potentiated
response to a low concentration of Bk (50 nM) after IL-1β was
blocked. On the other hand, calphostin C had no effect on the response
to Bk when it was applied after IL-β treatment. This indicates that PKC
was required to initiate the element that was responsible for the
potentiation, but not for its operation.
Direct measurement of free radical formation in single micro-
vessels proved not to be possible, but as a proof of principle we
established that IL-1β treatment enhances free radical generation in
small pieces of fresh rat brain tissue (Fig. 3D).
As we reported previously, the acute permeability response to
Bk depends on arachidonic acid formation via phospholipase A2
(PLA2) activation and subsequent ROS generation via cyclooxygen-
ase and lipoxygenase [13]. To examine whether IL-1β potentiates
free radical formation by making additional PLA2 isoforms available
we tested the effects of PLA2 inhibitors. Bromoenol lactone (BEL; aFig. 3. Possible signaling pathways in the potentiated response. (A) The permeability respon
the presence of SOD and catalase (paired data from eight vessels from eight rats; pb0.001,
(1 μM). The IL-1β-potentiated permeability response to Bk was unaffected by the soluble g
acute response to Bk when coapplied with the PKC inhibitor calphostin C, but when calphost
had no effect on the potentiated Bk response when it was applied with Bk after IL-1β treatme
by Amplex red. The tissue pretreated with IL-1β produced signiﬁcantly more ﬂuorescence w
multiple comparison test).calcium-independent PLA2 inhibitor when used at 0.4 μM) had no
effect (100 nM Bk post-IL-1β alone, 0.8±0.09×10−6 cm s−1, and
Bk with BEL, 0.8±0.2×10−6 cm s−1, four vessels from four rats for
each), whereas palmitoyl triﬂuoromethyl ketone (PACOCF3), which
at 100 μM inhibits all PLA2 isoforms [21] and was previously
shown to completely block the response to Bk when there was no
IL-1β pretreatment [13], reduced the response to Bk (100 nM)
post-IL-1β from 0.6±0.1×10−6 to 0.3±0.08×10−6 cm s−1 (four
vessels from four rats for each; see Fig 4A). Thus it seems that IL-
1β treatment resulted in an additional source of free radical
generation by Bk. This idea was tested by examining the effects of
the ﬂavoprotein inhibitor diphenylene iodonium (DPI; 100 μM),
which had no effect on the response to Bk before IL-1β treatment
(Bk 1 μM, 0.8±0.07, n=5; with DPI 100 μM, 0.8±0.10, n=4), but
did signiﬁcantly reduce the response to Bk (100 nM) after IL-1β
(0.8±0.04×10− 6 cm s− 1, n=3, to 0.4±0.04×10− 6 cm s− 1,
n=4). The combination of PACOCF3 with DPI almost abolished
the response to 10 nM Bk after IL-1β from 0.7±0.08×10−6 to
0.1±0.01×10−6 cm s−1 (n=4 for each). That the combination of
these high doses of PACOCF3 and DPI reduced the permeability
response to bradykinin after IL-1β by a signiﬁcantly greater degree
than either antagonist alone (pb0.01, ANOVA) is evidence that
pretreating with IL-1β for just 10 min produced an additional
source of bradykinin-stimulated ROS formation.
Application of apocynin, a more speciﬁc inhibitor of NADPH
oxidase than DPI, which has been suggested to act by preventing
its assembly, blocked the IL-1β potentiation (the log EC50 of the
bradykinin permeability responses being−6.52±0.32,−9.63±0.27,
and −6.48±0.34 for bradykinin alone, after IL-1β treatment, and
after IL-1β coapplied with apocynin 100 μM, respectively; Fig. 4B).se to bradykinin (50 nM), after pretreatment with IL-1β, was signiﬁcantly attenuated in
t test). (B) IL-1β treatment affected neither the baseline nor the response to histamine
uanylyl cyclase inhibitor ODQ (1 μM; four vessels from four rats). (C) No change in the
in C was coapplied with IL-1β the potentiated response to Bk was blocked. Calphostin C
nt (six vessels from six animals). (D) Free radical generation from brain tissuemeasured
ith bradykinin incubation for 15 min (eight brains; pb0.001, ANOVA with Bonferroni's
Fig. 4. Possible sources of ROS in the potentiated response. (A) The IL-1β-potentiated
response to Bk was reduced when either the PLA2 antagonist PACOCF3 or the
ﬂavoprotein inhibitor DPI was applied separately and was totally blocked when they
were applied together. All experiments were paired; four vessels from four animals. (B)
The leftward shift of the concentration–response curve for permeability was
completely blocked when apocynin (100 μM) was coapplied with IL-1β (30 pM; ﬁve
vessels from ﬁve animals).
Fig. 5. Localization of IL-1β effects to the endothelium. (A) The permeability response to
luminal bradykinin was attenuated by abluminal free radical scavenging (paired
experiments; four vessels from four animals; pb0.01, t test). (B) The permeability
response to abluminal bradykinin (0.5 μM) was increased after IL-1β application to the
vessel lumen (paired experiments; four vessels from four animals; pb0.01, t test).
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surface the responses to IL-1βwere due to cells other than endothelial
cells. This was addressed by applying IL-1β to the luminal side via
bolus injections of dye solution containing IL-1β (60 pM, as the ﬁnal
solution was mixed with blood) and trapping the solution in a
selected vessel for a total of 10 min (two or three applications).
Permeability responses to brain-side Bk (0.5 μM) increased on each
occasion (Fig. 5B). Similarly, the effects of free radical scavenging by
SOD and catalase were effective when applied to the brain side while
Bk was applied to the vessel lumen (Fig. 5A), which shows that this
mixture of scavengers is effective whether the free radicals are
generated inside or outside the cell membrane.
Discussion
Both bradykinin and IL-1β have been implicated in edema
formation after stroke and experimental cerebral ischemia, and
antagonizing each has been suggested as a therapeutic target for the
treatment of stroke [22,23]. The experiments described here provide
further evidence for a role for bradykinin and IL-1β in the early burst
of reactive oxygen species after cerebral ischemia–reperfusion. We
have also shown that a high concentration of bradykinin applied over
a number of minutes results in effects that are blocked by interleukin-
1 receptor antagonist. This implies that IL-1β is rapidly released from
brain tissue, which then activates NADPH oxidase to rapidly
potentiate the permeability response to bradykinin.
Starch microspheres were used to produce the reversible ischemia
because they produce a total block of a vascular territory by virtue of
occluding several small arterioles in parallel. This contrasts with the
middle cerebral artery occlusion technique, which generates a
reduction in blood ﬂow, but not necessarily a total cessation in thepial vessels studied here. The permeability increase measured within
2 or 3 min of reperfusion after the severe ischemia produced by the
starch microsphere infusion was reduced by scavenging free radicals,
which is consistent with the reported surge in free radical production
that occurs on reperfusion after 1 h of middle cerebral artery
occlusion [23]. There are several lines of evidence that indicate
bradykinin is the probable source of these free radicals. We have
previously shown that bradykinin application results in a free radical-
dependent permeability increase in normal rats [13], and in the
present experiments the B2 receptor antagonist, HOE 140, applied
after reperfusion produced a fall in permeability that reversed as soon
as it was removed (Fig. 1B). This indicates that bradykinin formation
continued after reperfusion and was not limited to the ischemic
period. The longer the blockage, the greater the cerebrovascular
permeability increase and bradykinin formation (Fig. 1D). Bradykinin
has been associated with free radical generation and associated tissue
damage on reperfusion in other preparations, too. Thus early on in
reperfusion bradykinin B2 receptor activation in the ischemic kidney
enhancesmalondialdehyde and H2O2 formation and reduces the GSH/
GSSG ratio as well as increasing tubular damage [24]. Furthermore, a
study [12] designed to examine changes in the kallikrein–kinin
system after middle cerebral artery occlusion (MCAO) and reperfu-
sion showed sustained bradykinin release that peaked at 12 h
postreperfusion. This was accompanied by an increased B2 receptor
density possibly requiring protein synthesis underlying the later
phase of permeability increase (see Figs. 2A and B).
The concept that bradykinin formation itself is a key trigger for
cerebrovascular dysfunction was ﬁrst suggested by Unterberg and
Baethemann [25]. This hypothesis, however, remains controversial
because although a number of studies have shown that inhibiting the
B2 receptor reduces cerebral damage [12,26], another study reported
that B2−/−mice aremore severely damaged after 90 min ofMCAO [27].
In the present model we have clear evidence that topical application
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rapid release of IL-1β (Figs. 2A and B). It is possible that bradykinin
acts on astrocytes to release ATP [28], which in turn rapidly releases
IL-1β from microglia via vesicle shedding [29]. On the other hand,
knocking out or blocking the P2X7 receptors for ATP had no effect on
ameliorating experimental cerebral ischemia [30]. Interestingly, as
bradykinin has recently been shown to reduce lipopolysaccharide-
stimulated release of IL-1β and TNF-α from isolated microglia [31], it
is possible that cytokine release after bradykinin production is
different in different preparations and depends on the cellular
distribution of B2 receptors.
There were two phases in the potentiation of cerebrovascular
permeability mediated by bradykinin produced by 10 min IL-1β
application. The second phase depended on new protein formation
involving possibly the formation of new kinin receptors [32]. The large
leftward displacement of the bradykinin concentration–response
curve is a novel ﬁnding (Fig. 2D).
The response to histamine was unaffected by IL-1β pretreatment,
indicating that the endothelium had not become generally more
responsive to all agonists (Fig. 3B) and is consistent with the
observation that IL-4 pretreatment but not IL-1β treatment increases
subsequent endothelial responses to histamine [33]. The permeability
response to acutely applied bradykinin is mediated via free radical
generation and particulate, not soluble, guanylyl cyclase, and
conversely the response to histamine is via soluble, not particulate,
guanylyl cyclase [19]. The possibility that IL-1β treatment led to
bradykinin recruiting soluble guanylyl cyclase for cGMP production
was excluded by our ﬁnding that the potentiated response was
insensitive to the soluble guanylyl cyclase inhibitor ODQ. Scavenging
free radicals inhibited the IL-1β-potentiated response as well as the
response before IL-1β [13], which points to an additional source of
free radicals. The possibility that this was due to additional activation
of PLA2 by IL-1β treatment, as observed in ﬁbroblasts [34] and after
cerebral ischemia [35], was tested by using PACOCF3 at a sufﬁciently
high concentration as to block all PLA2 isoforms [21]. We had
previously shown that this in the absence of IL-1β pretreatment
resulted in a complete abolition of the permeability response [13], but
here, after IL-1β, about 50% of the response remained. The
ﬂavoprotein inhibitor diphenylene iodonium also reduced the IL-1β-
potentiated response, but had no effect on the permeability increase
with no IL-1β pretreatment. The response was blocked when the two
inhibitors were given together, thus supporting the concept that an
additional ROS-generating pathway had been recruited.
It is likely that NADPH oxidase is a component of this additional
ROS pathway, as both apocynin application and blocking of PKC
during IL-1β treatment abolished the effect. The rapidity of the
inhibition by apocynin is probably due to the presence of peroxidases
that result in the formation of the active apocynin dimer [36]. PKC is
required for p47phox phosphorylation, a key element of the prepara-
tion of NADPH oxidase for its activation [21], and it is not required for
the acute response to bradykinin alone [37]; blocking it after NADPH
oxidase assembly did not affect the potentiated response once it had
been established.
Bradykinin, IL-1β, and other substances were usually applied on
the brain surface to the abluminal side of the microvessels, which
exposed other cells to their effects. Some experiments were carried
out to investigate whether the effects of IL-1βwere due to endothelial
cells alone by applying it luminally by injecting it with a dye bolus and
so limiting its access to the apical surface of the endothelium. The
potentiation of the permeability response was not altered (Fig. 5B),
and furthermore, applying the free radical-scavenging mixture of SOD
and catalase to the abluminal surface was effective in reducing the
permeability response to bradykinin applied to the lumen (Fig. 5A). It
is likely that the effects of superoxide are not as tightly localized as
once believed, as it has been shown that superoxide itself permeates
cell membranes via anionic channels [38], and it is also possible thatintracellular SOD generates H2O2 that will permeate cell membranes
and so be subject to the extremely effective free radical-scavenging
system provided by the mixture of SOD and catalase.
The direct measurement of free radical generation in brain tissue
shows that the response to bradykinin became detectable only after
the tissue had been exposed to IL-1β for 10 min. This time course is
consistent with the ﬁnding that TNF-α applied to endothelial cells
results in p47phox phosphorylation, and 5 min exposure leads to about
70% of the maximal phosphorylation [10]. IL-1β has also been shown
to increase the permeability response to a low concentration of
bradykinin in the hamster cheek pouch [39].
IL-1β alone rapidly (within 10 to 15 min of its application)
increases superoxide formation in both cultured endothelial cells
[40] and retinal pigment epithelial cells, the latter with evidence
that NADPH oxidase activation was involved [41]. These data are
consistent with the present observation that IL-1β itself results in a
small permeability increase (see Figs. 2C and 3A). The potentiation
of the response to bradykinin after just a brief exposure to a
modest concentration of IL-1β is a novel ﬁnding. The indication
that NADPH oxidase assembly is the key step in this process has
important implications for understanding the development of
cerebral edema as a consequence of the cascade of events that
follow ischemia–reperfusion.
In conclusion, we have investigated the mechanisms involved in
cerebral edema formation after ischemia and reperfusion. It has been
clear for some time that bradykinin and IL-1β, with other substances,
are involved in a cascade of events that leads to a large disruption of
the blood–brain barrier [42,43], which is the basis of vasogenic edema.
Herewe have shown for the ﬁrst time that bradykinin, released during
ischemia, leads to IL-1β release, which in turn results in rapid
potentiation of the permeability response to bradykinin via assembly
of NADPH oxidase.
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